Trial Information

Summary: Protocol PR1-104 - Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study

You have been asked to participate in this research study because you have acute myelogenous leukemia (AML) with poor prognostic features that is in either first or second complete remission (not evidence of disease by standard clinical tests).  The purpose of this research study is to compare a vaccine called PR1 to a placebo injection containing no active vaccine in terms of side effects and effectiveness at prolonging complete remission.  Your participation in this study is expected to last 5-6 months for treatment.  After your treatment on this study is over, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:41:11 PM